Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Ludden

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Hypertension (Dallas, Tex. : 1979)|September 1, 1981
Plasma concentration and acetylator phenotype determine response to oral hydralazineA M Shepherd, J L McNay, T M Ludden, et al.
Clinical Pharmacology and Therapeutics|November 1, 1984
Effect of oral dose size on hydralazine kinetics and vasodepressor responseA M Shepherd, N A Irvine, T M Ludden, et al.
Research Communications in Chemical Pathology and Pharmacology|November 1, 1986
Measurement of WR-1065 in plasma: preliminary pharmacokinetics in the beagleN F Swynnerton, B K Huelle, E P McGovern, et al.
Therapeutic Drug Monitoring|January 1, 1989
Evaluation of a Bayesian regression program for predicting warfarin responseD A Boyle, T M Ludden, B L Carter, et al.
Pharmacotherapy|January 1, 1989
Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trialsN M Graves, T M Ludden, G B Holmes, et al.
Journal of Pharmaceutical Sciences|December 1, 1988
Relative bioavailability of immediate- and sustained-release hydralazine formulationsT M Ludden, K S Rotenberg, L K Ludden, et al.
Clinical Pharmacy|August 1, 1987
Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrationsP J Godley, T M Ludden, W A Clementi, et al.
Therapeutic Drug Monitoring|January 1, 1989
Clinical utility of a Bayesian dosing program for phenytoinM D Privitera, R W Homan, T M Ludden, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading doseJ J Crowley, J R Koup, B J Cusack, et al.
Journal of Pharmaceutical Sciences|June 1, 1992
Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challengeJ R Woodworth, T M Ludden, L K Ludden, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Hypertension (Dallas, Tex. : 1979)|September 1, 1981
Plasma concentration and acetylator phenotype determine response to oral hydralazineA M Shepherd, J L McNay, T M Ludden, et al.
Clinical Pharmacology and Therapeutics|November 1, 1984
Effect of oral dose size on hydralazine kinetics and vasodepressor responseA M Shepherd, N A Irvine, T M Ludden, et al.
Research Communications in Chemical Pathology and Pharmacology|November 1, 1986
Measurement of WR-1065 in plasma: preliminary pharmacokinetics in the beagleN F Swynnerton, B K Huelle, E P McGovern, et al.
Therapeutic Drug Monitoring|January 1, 1989
Evaluation of a Bayesian regression program for predicting warfarin responseD A Boyle, T M Ludden, B L Carter, et al.
Pharmacotherapy|January 1, 1989
Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trialsN M Graves, T M Ludden, G B Holmes, et al.
Journal of Pharmaceutical Sciences|December 1, 1988
Relative bioavailability of immediate- and sustained-release hydralazine formulationsT M Ludden, K S Rotenberg, L K Ludden, et al.
Clinical Pharmacy|August 1, 1987
Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrationsP J Godley, T M Ludden, W A Clementi, et al.
Therapeutic Drug Monitoring|January 1, 1989
Clinical utility of a Bayesian dosing program for phenytoinM D Privitera, R W Homan, T M Ludden, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading doseJ J Crowley, J R Koup, B J Cusack, et al.
Journal of Pharmaceutical Sciences|June 1, 1992
Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challengeJ R Woodworth, T M Ludden, L K Ludden, et al.
Pageof 13